Lenvatinib (Lenv) plus tislelizumab (Tis) combined with or without transarterial chemoembolization (TACE) in first-line treatment of unresectable hepatocellular carcinoma (uHCC): A prospective, non-randomized, open-label, phase II cohort study.

被引：0

作者：

Zhang, Nan

Li, Jiongyuan

Piao, Mingjian

Li, Chengjie

Xun, Ziyu

Zhang, Longhao

Wang, Yanyu

Liu, Kai

Wang, Shanshan

Wang, Hanping

Zhao, Hai-Tao

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Liver Surg, State Key Lab Complex Severe & Rare Dis, Beijing, Peoples R China

[2] Peking Union Med Coll & Chinese Acad Med Sci, Div Pulm & Crit Care Med, State Key Lab Severe & Rare Dis, Beijing, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e16169

引用

页数：1

共 50 条

[41] Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Qin, Shukui
Chan, Stephen L.
Gu, Shanzhi
Bai, Yuxian
Ren, Zhenggang
Lin, Xiaoyan
Chen, Zhendong
Jia, Weidong
Jin, Yongdong
Guo, Yabing
Hu, Xiaohua
Meng, Zhiqiang
Liang, Jun
Cheng, Ying
Xiong, Jianping
Ren, Hong
Yang, Fang
Li, Wei
Chen, Yajin
Zeng, Yong
Sultanbaev, Alexander
Pazgan-Simon, Monika
Pisetska, Margaryta
Melisi, Davide
Ponomarenko, Dmitriy
Osypchuk, Yurii
Sinielnikov, Ivan
Yang, Tsai-Sheng
Liang, Xiao
Chen, Chunxia
Wang, Linna
Cheng, Ann-Lii
Kaseb, Ahmed
Vogel, Arndt
LANCET, 2023, 402 (10408): : 1133 - 1146
[42] A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma
Thomas, Melanie B.
Garrett-Mayer, Elizabeth
Anis, Munazza
Anderton, Kate
Bentz, Tricia
Edwards, Andie
Brisendine, Alan
Weiss, Geoffrey
Siegel, Abby B.
Bendell, Johanna
Baron, Ari
Duddalwar, Vinay
El-Khoueiry, Anthony
ONCOLOGY, 2018, 94 (06) : 329 - 339
[43] An investigation of the safety of continued treatment with sorafenib in patients with unresectable hepatocellular carcinoma after the first disease progression: Multicenter, open-label, phase II safety study.
Akutsu, Noriyuki
Sasaki, Shigeru
Takagi, Hideyasu
Kaneto, Hiroyuki
Yonezawa, Kazuhiko
Yawata, Atsushi
Adachi, Takeya
Yokoo, Hideki
Kamiyama, Toshiya
Hamamoto, Yasuo
Shinomura, Yasuhisa
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[44] Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study
Yan, X. Q.
Yey, M. J.
Zou, Q.
Chen, P.
He, Z. S.
Wu, B.
He, D. L.
He, C. H.
Xue, X. Y.
Ji, Z. G.
Chen, H.
Zhang, S.
Liu, Y. P.
Zhang, X. D.
Fu, C.
Xu, D. F.
Qiu, M. X.
Lv, J. J.
Huang, J.
Ren, X. B.
Cheng, Y.
Qin, W. J.
Zhang, X.
Zhou, F. J.
Ma, L. L.
Guo, J. M.
Ding, D. G.
Wei, S. Z.
He, Y.
Guo, H. Q.
Shi, B. K.
Liu, L.
Liu, F.
Hu, Z. Q.
Jin, X. M.
Yang, L.
Zhu, S. X.
Liu, J. H.
Huang, Y. H.
Xu, T.
Liu, B.
Sun, T.
Wang, Z. J.
Jiang, H. W.
Yu, D. X.
Zhou, A. P.
Jiang, J.
Luan, G. D.
Jin, C. L.
Xu, J.
ANNALS OF ONCOLOGY, 2024, 35 (02) : 190 - 199
[45] REPLACE: A phase III, randomized, open-label trial to evaluate the safety and efficacy of regorafenib and pembrolizumab versus locoregional therapy (LRT) with transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), for the first-line treatment of intermediate-stage hepatocellular carcinoma (HCC) with beyond up-to-7 criteria
Galle, Peter Robert
Kudo, Masatoshi
Llovet, Josep M.
Cheng, Ann-Lii
Lencioni, Riccardo
Oviedo, Yanina
Desai, Kalpna
Monier, Amandine
Finn, Richard S.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[46] An open-label, multicenter, adaptive, phase Ib/II study of QL1706 or QL1604 plus bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma
Bi, Feng
Zhang, Yan-Qiao
Gu, Shanzhi
Guo, Yabing
Xu, Zhongyuan
Ying, Hao
Da, Mingxu
Liu, Chaoying
Pan, Yaozhen
Huang, Yao
Chen, Zhiyu
Wang, Zheng
Wu, Jianbing
Weng, Shangeng
Wang, Yanjun
Zhao, Jun
Yu, Xiaokui
Li, Hui
Xue, Shilin
Kang, Xiaoyan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[47] Efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, open-label, multicenter study - Trial in progress
Qin, S.
Finn, R.
Kudo, M.
Meyer, T.
Vogel, A.
Ducreux, M.
Macarulla, T.
Tomasello, G.
Boisserie, F.
Hou, J.
Li, C.
Song, J.
Zhu, A.
ANNALS OF ONCOLOGY, 2018, 29
[48] A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.
Qin, Shukui
Finn, Richard S.
Kudo, Masatoshi
Meyer, Tim
Vogel, Arndt
Ducreux, Michel
Mercade, Teresa Macarulla
Tomasello, Gianluca
Boisserie, Frederic
Hou, Jeannie
Li, Cindy
Song, James
Zhu, Andrew X.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[49] AdvanTIG-206: Phase II randomized open-label study of ociperlimab (OCI) plus tislelizumab (TIS)+BAT1706 (bevacizumab biosimilar) versus TIS+BAT1706 in patients (pts) with advanced hepatocellular carcinoma (HCC)
Ren, Z.
Huang, Y.
Guo, Y.
Hou, M. M.
Wang, W.
Kuang, M.
Hao, C.
Wang, W.
Zhang, Y.
Song, T.
Dai, C.
Hsing-Tao, K.
Li, V.
Abdrashitov, R.
Wang, L.
Fan, J.
ANNALS OF ONCOLOGY, 2023, 34 : S594 - S594
[50] Camrelizumab combined with SOX in the first-line treatment of unresectable advanced or metastatic gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, prospective, and open-label clinical study.
Liu, Wenlou
Qin, Xiaobing
Zhao, Yang
Ge, Yan
Tang, Juanjuan
Wang, Hongmei
Han, Zhengxiang
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16090 - E16090

← 1 2 3 4 5 →